Eumycetoma: pathogenesis, current treatments, and the search for new drugs
Applied Microbiology and Biotechnology · 19.08.2025 · 109 (1)
DOI: 10.1007/s00253-025-13580-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 19.08.2025. Verfasst von Dounia El Yachioui und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands. Hauptthemen laut MEDLINE: Mycetoma, Antifungal Agents, Drug Repositioning. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Eumycetoma is a neglected tropical disease which can be caused by 69 different fungal species. In 2024, eumycetoma was listed as a high priority fungal infection on the fungal priority list of the World Health Organization. Eumycetoma is characterized by chronic subcutaneous swelling, the formation of grains, and progressive tissue destruction. If left untreated, it can lead to severe complications such as bone destruction and permanent disability. Current antifungal treatments, such as itraconazole and terbinafine, are lengthy and often ineffective without surgical intervention. The search for novel treatments is challenging due to limited interest and return of investment. Drug repurposing has emerged as a promising strategy for discovering new effective therapies against eumycetoma. Additionally, the MycetOS initiative focuses on developing novel antifungal compounds that are tested in vitro and in vivo. KEY POINTS: Pathogenesis involves the formation of grains to protect the fungus New treatments are needed for eumycetoma to reduce recurrence and amputation rates Drug repurposing and MycetOS are key strategies for developing new treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
- Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands. w.vandesande@erasmusmc.nl.
Förderung
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Yachioui, D. E., Baltussen, T., & van de Sande, W. W. J. (2025). Eumycetoma: pathogenesis, current treatments, and the search for new drugs. Applied Microbiology and Biotechnology, 109(1). https://doi.org/10.1007/s00253-025-13580-5
Vancouver
Yachioui DE, Baltussen T, van de Sande WWJ. Eumycetoma: pathogenesis, current treatments, and the search for new drugs. Applied Microbiology and Biotechnology. 2025;109(1). doi:10.1007/s00253-025-13580-5
BibTeX
@article{Yachioui2025,
author = {Yachioui, Dounia El and Baltussen, Tim and van de Sande, Wendy W J},
title = {Eumycetoma: pathogenesis, current treatments, and the search for new drugs},
journal = {Applied Microbiology and Biotechnology},
year = {2025},
volume = {109},
number = {1},
doi = {10.1007/s00253-025-13580-5}
}
EUVIMED